Jorge Alex Alvarez, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anthracyclines | 4 | 2017 | 285 | 0.670 |
Why?
|
Ventricular Function, Left | 3 | 2024 | 3873 | 0.600 |
Why?
|
Gated Blood-Pool Imaging | 1 | 2017 | 42 | 0.580 |
Why?
|
Cardiomyopathy, Dilated | 3 | 2011 | 831 | 0.360 |
Why?
|
Endocrine System Diseases | 1 | 2007 | 249 | 0.230 |
Why?
|
Heart Transplantation | 3 | 2011 | 3233 | 0.190 |
Why?
|
Registries | 3 | 2011 | 8209 | 0.160 |
Why?
|
Stroke Volume | 3 | 2024 | 5486 | 0.150 |
Why?
|
Antineoplastic Agents | 3 | 2017 | 13635 | 0.140 |
Why?
|
Neoplasms | 4 | 2017 | 22131 | 0.120 |
Why?
|
Myocarditis | 2 | 2011 | 788 | 0.110 |
Why?
|
Cognition Disorders | 1 | 2007 | 3979 | 0.100 |
Why?
|
Echocardiography | 2 | 2024 | 4987 | 0.100 |
Why?
|
Ventricular Remodeling | 2 | 2010 | 1265 | 0.100 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2017 | 1068 | 0.100 |
Why?
|
Heart | 2 | 2017 | 4403 | 0.080 |
Why?
|
Heart Ventricles | 2 | 2017 | 3796 | 0.070 |
Why?
|
Morbidity | 1 | 2011 | 1750 | 0.060 |
Why?
|
Time | 1 | 2007 | 545 | 0.060 |
Why?
|
Waiting Lists | 1 | 2009 | 764 | 0.060 |
Why?
|
Heart Diseases | 2 | 2008 | 2778 | 0.060 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2007 | 678 | 0.050 |
Why?
|
Patient Selection | 2 | 2011 | 4237 | 0.050 |
Why?
|
Cardiovascular Diseases | 1 | 2007 | 15498 | 0.050 |
Why?
|
Heart Failure | 2 | 2017 | 11670 | 0.040 |
Why?
|
Survival Analysis | 1 | 2011 | 10072 | 0.040 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2009 | 2118 | 0.040 |
Why?
|
Disease-Free Survival | 1 | 2007 | 6807 | 0.030 |
Why?
|
Child, Preschool | 4 | 2011 | 42193 | 0.030 |
Why?
|
Child | 5 | 2011 | 80089 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2011 | 15250 | 0.030 |
Why?
|
Infant | 3 | 2011 | 36157 | 0.030 |
Why?
|
Infant, Newborn | 2 | 2011 | 26183 | 0.030 |
Why?
|
Humans | 8 | 2024 | 760740 | 0.030 |
Why?
|
Risk Assessment | 2 | 2011 | 23974 | 0.030 |
Why?
|
Risk Factors | 4 | 2011 | 74128 | 0.020 |
Why?
|
Adolescent | 2 | 2011 | 88247 | 0.020 |
Why?
|
Survival | 1 | 2010 | 161 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2011 | 39062 | 0.020 |
Why?
|
Dilatation, Pathologic | 1 | 2009 | 527 | 0.020 |
Why?
|
Razoxane | 1 | 2007 | 43 | 0.020 |
Why?
|
Male | 5 | 2011 | 360402 | 0.020 |
Why?
|
Female | 5 | 2011 | 392203 | 0.020 |
Why?
|
Drug Interactions | 1 | 2007 | 1415 | 0.010 |
Why?
|
Drug Monitoring | 1 | 2007 | 960 | 0.010 |
Why?
|
Cardiovascular Agents | 1 | 2007 | 840 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2009 | 6473 | 0.010 |
Why?
|
Insurance, Health | 1 | 2009 | 2495 | 0.010 |
Why?
|
Ultrasonography | 1 | 2009 | 5965 | 0.010 |
Why?
|
Medicaid | 1 | 2009 | 2814 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2008 | 10754 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2009 | 12448 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2010 | 64572 | 0.010 |
Why?
|
Age Factors | 1 | 2009 | 18381 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2009 | 15829 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2010 | 80583 | 0.010 |
Why?
|
Time Factors | 1 | 2009 | 39908 | 0.000 |
Why?
|
Cohort Studies | 1 | 2010 | 41464 | 0.000 |
Why?
|
Prospective Studies | 1 | 2009 | 54364 | 0.000 |
Why?
|
United States | 1 | 2009 | 72292 | 0.000 |
Why?
|